EnGene Therapeutics Shares Sink After Cancer Study Durability Outcomes Disappoint

Dow Jones05-07

By Nicholas G. Miller

Shares of EnGene Therapeutics plummeted after the company reported disappointing durability outcomes from a Phase 2 trial of its detalimogene voraplasmid drug for bladder cancer patients.

The stock fell 73% to $2.36 in premarket trading. Through Wednesday's close, shares had more than doubled over the past 12 months.

The company said the estimate for median duration of response was 37.3 weeks. The estimate of the 12-month duration of response was 25%.

"While durability outcomes to date are not what we hoped, these data are preliminary," said Chief Executive Ron Cooper.

EnGene also said that among the 32 patients who had their first disease assessment after the last data analysis, complete response rates were lower than previously reported results.

Write to Nicholas G. Miller at nicholas.miller@wsj.com.

(END) Dow Jones Newswires

May 07, 2026 09:15 ET (13:15 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2633407241?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-07 21:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2633407241","market":"us","top_or_hot":-1,"title":"EnGene Therapeutics Shares Sink After Cancer Study Durability Outcomes Disappoint","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of EnGene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plummeted after the company reported disappointing durability outcomes from a Phase 2 trial of its detalimogene voraplasmid drug for bladder cancer patients. \n</p>\n<p>\n  The stock fell 73% to $2.36 in premarket trading. Through Wednesday's close, shares had more than doubled over the past 12 months. \n</p>\n<p>\n  The company said the estimate for median duration of response was 37.3 weeks. The estimate of the 12-month duration of response was 25%. \n</p>\n<p>\n  \"While durability outcomes to date are not what we hoped, these data are preliminary,\" said Chief Executive Ron Cooper. \n</p>\n<p>\n  EnGene also said that among the 32 patients who had their first disease assessment after the last data analysis, complete response rates were lower than previously reported results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2026 09:15 ET (13:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>EnGene Therapeutics Shares Sink After Cancer Study Durability Outcomes Disappoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEnGene Therapeutics Shares Sink After Cancer Study Durability Outcomes Disappoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-05-07 21:15</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Nicholas G. Miller \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of EnGene <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> plummeted after the company reported disappointing durability outcomes from a Phase 2 trial of its detalimogene voraplasmid drug for bladder cancer patients. \n</p>\n<p>\n  The stock fell 73% to $2.36 in premarket trading. Through Wednesday's close, shares had more than doubled over the past 12 months. \n</p>\n<p>\n  The company said the estimate for median duration of response was 37.3 weeks. The estimate of the 12-month duration of response was 25%. \n</p>\n<p>\n  \"While durability outcomes to date are not what we hoped, these data are preliminary,\" said Chief Executive Ron Cooper. \n</p>\n<p>\n  EnGene also said that among the 32 patients who had their first disease assessment after the last data analysis, complete response rates were lower than previously reported results. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  May 07, 2026 09:15 ET (13:15 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2633407241","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2633407241","pubTimestamp":1778159700,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of EnGene Therapeutics plummeted after the company reported disappointing durability outcomes from a Phase 2 trial of its detalimogene voraplasmid drug for bladder cancer patients.The stock fell 73% to $2.36 in premarket trading. Through Wednesday's close, shares had more than doubled over the past 12 months.The company said the estimate for median duration of response was 37.3 weeks. The estimate of the 12-month duration of response was 25%.\"While durability outcomes to date are not what we hoped, these data are preliminary,\" said Chief Executive Ron Cooper.EnGene also said that among the 32 patients who had their first disease assessment after the last data analysis, complete response rates were lower than previously reported results.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","ENGN":"ENGENE HOLDINGS INC","BK4139":"生物科技","LENZ":"Therapeutics","BK4007":"制药"},"translate_title":"癌症研究持久性结果令人失望后，EnGene Therapeutics股价下跌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LENZ":1.5,"ENGN":0.9},"content_text":"By Nicholas G. Miller \n\n\n \n\n\n  Shares of EnGene Therapeutics plummeted after the company reported disappointing durability outcomes from a Phase 2 trial of its detalimogene voraplasmid drug for bladder cancer patients. \n\n\n  The stock fell 73% to $2.36 in premarket trading. Through Wednesday's close, shares had more than doubled over the past 12 months. \n\n\n  The company said the estimate for median duration of response was 37.3 weeks. The estimate of the 12-month duration of response was 25%. \n\n\n  \"While durability outcomes to date are not what we hoped, these data are preliminary,\" said Chief Executive Ron Cooper. \n\n\n  EnGene also said that among the 32 patients who had their first disease assessment after the last data analysis, complete response rates were lower than previously reported results. \n\n\n \n\n\n  Write to Nicholas G. Miller at nicholas.miller@wsj.com. \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  May 07, 2026 09:15 ET (13:15 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2633407241","isCrawlerRequest":true}